RU2018114533A - Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options) - Google Patents

Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options) Download PDF

Info

Publication number
RU2018114533A
RU2018114533A RU2018114533A RU2018114533A RU2018114533A RU 2018114533 A RU2018114533 A RU 2018114533A RU 2018114533 A RU2018114533 A RU 2018114533A RU 2018114533 A RU2018114533 A RU 2018114533A RU 2018114533 A RU2018114533 A RU 2018114533A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
glyceryl
treatment
targeted delivery
Prior art date
Application number
RU2018114533A
Other languages
Russian (ru)
Other versions
RU2018114533A3 (en
Inventor
Кенес Тагаевич Еримбетов
Ксения Юрьевна Власова
Руслан Александрович Земляной
Елена Сергеевна Фрог
Екатерина Валерьевна Бондаренко
Анна Яковлевна Гончарова
Рахимджан Ахметджанович Розиев
Original Assignee
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" filed Critical Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм"
Priority to RU2018114533A priority Critical patent/RU2018114533A/en
Priority to PCT/RU2019/050048 priority patent/WO2019203697A1/en
Priority to EA202092218A priority patent/EA202092218A1/en
Publication of RU2018114533A publication Critical patent/RU2018114533A/en
Publication of RU2018114533A3 publication Critical patent/RU2018114533A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (12)

1. Фармацевтическая композиция на основе твердых липидных частиц гидрохлорида 1-{[6-бром-1-метил-5-метокси-2-фенилтиометил-1-Н-индол-3-ил]карбонил}-4 бензилпиперазина, обладающая свойством направленной доставки для лечения гриппа и ОРВИ, при следующем соотношении компонентов, мас. %:1. Pharmaceutical composition based on solid lipid particles of 1 - {[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-H-indol-3-yl] carbonyl} -4 benzylpiperazine hydrochloride, with targeted delivery for the treatment of influenza and SARS, in the following ratio of components, wt. %: Гидрохлорид 1-{[6-бром-1- метил-5-метокси-2-фенилтиометил-1-Н-индол-3-ил]карбонил}-4 бензилпиперазинHydrochloride 1 - {[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-H-indol-3-yl] carbonyl} -4 benzylpiperazine 2,0-14,02.0-14.0 Глицерид длинноцепочечных жирных кислотLong chain fatty acid glyceride 64,0-86,064.0-86.0 Масло растительноеVegetable oil 10,0-20,0 10.0-20.0 ЭмульгаторEmulsifier 2,0 2.0
2. Фармацевтическая композиция по п. 1, отличающаяся тем, что дополнительно содержит триглицерид среднецепочечный при следующем соотношении компонентов, мас. %:2. The pharmaceutical composition according to p. 1, characterized in that it further comprises medium chain triglyceride in the following ratio of components, wt. %: Гидрохлорид 1-{[6-бром-1- метил-5-метокси-2-фенилтиометил-1-Н-индол-3-ил]карбонил}-4 бензилпиперазинHydrochloride 1 - {[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-H-indol-3-yl] carbonyl} -4 benzylpiperazine 2,0-14,02.0-14.0 Глицерид длинноцепочечных жирных кислотLong chain fatty acid glyceride 50-70,0 50-70,0 Масло растительноеVegetable oil 10,0-30,0 10.0-30.0 Триглицерид среднецепочечный Medium Chain Triglyceride 4,0-16,04.0-16.0 ЭмульгаторEmulsifier 2,0 2.0
3. Фармацевтическая композиция по пп. 1 и 2, отличающееся тем, что глицерид длинноцепочечных жирных кислот выбран из глицерил тристеарата, глицерилдистеарата, глицерилмоностеарата, глицерилпальмитата, глицерилдибегената, глицерилтрибегената, глицерилмоноолеата, белого воска или воска цетиловых эфиров.3. The pharmaceutical composition according to paragraphs. 1 and 2, characterized in that the long chain fatty acid glyceride is selected from glyceryl tristearate, glyceryl distearate, glyceryl monostearate, glyceryl palmitate, glyceryl dibehenate, glyceryl tribenegen, glyceryl monooleate, white wax or wax. 4. Фармацевтическая композиция по пп. 1 и 2, отличающаяся тем, что масло растительное выбрано из группы, например, масла оливкового, арахисового, кунжутного, льняного, рапсового, соевого, хлопкового, лимонного, апельсинового.4. The pharmaceutical composition according to paragraphs. 1 and 2, characterized in that the vegetable oil is selected from the group of, for example, olive, peanut, sesame, linseed, rapeseed, soybean, cotton, lemon, orange. 5. Фармацевтическая композиция по п. 2, отличающаяся тем, что триглицерид среднецепочечный выбран в виде масла кокосового, пальмового или пальмоядрового.5. The pharmaceutical composition according to claim 2, characterized in that the medium chain triglyceride is selected in the form of coconut, palm or palm kernel oil. 6. Фармацевтическая композиция по пп. 1 и 2, отличающаяся тем, что эмульгатор выбран из лецитина или желатина.6. The pharmaceutical composition according to paragraphs. 1 and 2, characterized in that the emulsifier is selected from lecithin or gelatin. 7. Лекарственный препарат, обладающий свойством адресной доставки для лечения гриппа и ОРВИ, содержащий фармацевтическую композицию по п.1 или 2, выполнен в виде таблеток или пилюль.7. A drug having the property of targeted delivery for the treatment of influenza and SARS, containing the pharmaceutical composition according to claim 1 or 2, is made in the form of tablets or pills. 8. Лекарственный препарат, обладающий свойством адресной доставки для лечения гриппа и ОРВИ, содержащий фармацевтическую композицию по п. 1 или 2, выполнен в виде желатиновых капсул.8. A drug having the property of targeted delivery for the treatment of influenza and acute respiratory viral infections, containing the pharmaceutical composition according to claim 1 or 2, is made in the form of gelatin capsules. 9. Лекарственный препарат по п. 8, отличающийся тем, что желатиновые капсулы твердые и/или мягкие.9. The drug according to claim 8, characterized in that the gelatin capsules are hard and / or soft. 10. Лекарственный препарат по п. 7 или 8, отличающийся тем, что содержание гидрохлорид 1-{[6-бром-1-метил-5-метокси-2-фенилтиометил-1-Н-индол-3-ил]карбонил}-4 бензилпиперазина составляет от 2 до 14%.10. The drug according to claim 7 or 8, characterized in that the content of 1 - {[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-H-indol-3-yl] carbonyl} hydrochloride} - 4 benzylpiperazine ranges from 2 to 14%.
RU2018114533A 2018-04-19 2018-04-19 Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options) RU2018114533A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
RU2018114533A RU2018114533A (en) 2018-04-19 2018-04-19 Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options)
PCT/RU2019/050048 WO2019203697A1 (en) 2018-04-19 2019-04-19 Composition for treating viral diseases (variants)
EA202092218A EA202092218A1 (en) 2018-04-19 2019-04-19 COMPOSITION FOR TREATMENT OF VIRAL DISEASES (VERSIONS)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018114533A RU2018114533A (en) 2018-04-19 2018-04-19 Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options)

Publications (2)

Publication Number Publication Date
RU2018114533A true RU2018114533A (en) 2019-10-21
RU2018114533A3 RU2018114533A3 (en) 2020-05-12

Family

ID=68239039

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018114533A RU2018114533A (en) 2018-04-19 2018-04-19 Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options)

Country Status (3)

Country Link
EA (1) EA202092218A1 (en)
RU (1) RU2018114533A (en)
WO (1) WO2019203697A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435582C1 (en) * 2010-10-05 2011-12-10 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Medication against b influenza virus
RU2448120C1 (en) * 2010-11-01 2012-04-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Clathrate complexes of beta-cyclodextrin with 1-{[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-h-indol-3-yl]carbonyl}-4-benzylpiperazine, having antiviral activity, synthesis and use thereof
KR20140031227A (en) * 2011-03-24 2014-03-12 레오 파마 에이/에스 A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
EP2821077A1 (en) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing

Also Published As

Publication number Publication date
WO2019203697A1 (en) 2019-10-24
RU2018114533A3 (en) 2020-05-12
EA202092218A1 (en) 2021-01-25

Similar Documents

Publication Publication Date Title
JP2022164892A (en) Ophthalmic aqueous composition
RU2007103835A (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE EYE CONDITION
AR114051A2 (en) PHARMACEUTICAL COMPOSITIONS AND VAGINAL SUPPOSITORY
JP2013508296A5 (en)
RU2008103363A (en) COMPOSITIONS FOR IMPROVING THE DEPRECATED FUNCTION OF THE HIGHER DIVISIONS OF THE BRAIN ARISING AS A RESULT OF ORGANIC DAMAGE OF THE BRAIN
Bahmani et al. Physalis alkekengi: A review of its therapeutic effects
RU2009133338A (en) COMPOSITIONS CONTAINING EXTRACTS OF CYNARA SCOLYMUS AND PHASEOLUS VULGARIS, WHICH ARE USEFUL FOR TREATING OBESITY
JP2023060015A (en) ophthalmic composition
RU2017129161A (en) LIPID COMPOSITIONS
TW201620502A (en) Ophthalmologic or otorhinologic aqueous composition
RU2018114533A (en) Composition based on solid lipid particles with the property of targeted delivery for the treatment of viral diseases (options)
JP2013155369A (en) Shirasu soap (volcanic ash soap)
AR063055A1 (en) IMPROVEMENT OF THE BIOLOGICAL ACTION OF AGROCHEMICAL COMPOSITIONS IN CASE OF APPLICATION IN THE MEDIA, APPROPRIATE FORMULATIONS AND ITS USE
RU2007137251A (en) HEPATOPROTECTIVE, DETOXING AND REGENERATING ACTION
KR20060100117A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING alpha;-LIPOIC ACID WITH IMPROVED STABILITY
GEP20237543B (en) Pharmaceutical composition comprising omega fatty acids, and infusion preparation comprising the same
CN1732902A (en) Vitamin contained spray
ATE357934T1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING THE DEVELOPMENT AND PROGRESSION OF MYCOTIC SURFACE DISEASES
JP7412871B2 (en) External composition
RU2005140782A (en) COMPOSITION FOR INCREASING THE RESISTANCE OF THE ORGANISM TO UNFAVORABLE ENVIRONMENTAL FACTORS AND PREVENTION OF ONCOLOGICAL RISK
JP7086597B2 (en) External composition
RU2009143215A (en) COMPOSITION OF MEDICINAL PHYTOSUBSTANTS WITH ANTI-MICROBIAL AND ANTI-INFLAMMATORY PROPERTIES OF "DENTOS"
ES2616831B1 (en) COSMETIC PRODUCT
JP7412870B2 (en) External composition
RU2005104630A (en) EYE CREAM

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201020